HHS's Leavitt: no price controls for us, thanks

Share this article:
With the Democrats set to take over Congress in January and vowing to empower Health and Human Services to negotiate drug prices directly with companies, HHS Secretary Michael Leavitt said: Thanks, but no thanks. Leavitt told The New York Times direct negotiation of drug prices, forbidden under the Medicare Modernization Act as currently written, would wreck the drug benefit. “Democrats say they want the government to negotiate prices,” said Leavitt. “What they really want is government-run health care.” Speaker-elect Nancy Pelosi (D-CA) has vowed to pass legislation allowing government price negotiations within the first 100 hours after Democrats assume control of the House. Pelosi and Sen. Dick Durbin (D-IL), the Senate Democrats’ No. 2, have sponsored legislation that would create one or more government-run Medicare plans to run alongside the private plans and require HHS to negotiate prices for it. Leavitt, echoing a post-election PhRMA release, noted that the private plans are already in large-scale negotiations with drug companies, and that beneficiaries of the program are reaping deep discounts. “It’s the magic of the market,” said Leavitt. “To assume that the government, in our genius, could improve on this belies the reality of a complex task.” In an editorial, The Times opined: “Democrats should give it to him anyway.”
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...